OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$12.17
+0.00%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.48
- Revenue estimate
- $267.4K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.20
- EPS estimate
- -$0.48
- Revenue actual
- $371.1K
- Revenue estimate
- $216.8K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -0.0%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $23
- PT range
- $20 – $26
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026